

Certificate



Quality Management System
EN ISO 13485:2016

Registration No.: SX 1483000-1

Organization: EUROIMMUN
Medizinische Labordiagnostika AG
Seekamp 31
23560 Lübeck
Germany

Scope: Design and development, manufacture, installation, service and distribution of immuno-biochemical test systems, immunofluorescence test systems, molecular diagnostic / genetic test systems, test systems for the determination of infectious agents, and instruments / software for in vitro diagnostics

TÜVRheinland

The Certification Body of TÜV Rheinland LGA Products GmbH certifies that the organization has established and applies a quality management system for medical devices. Proof has been furnished that the requirements specified in the abovementioned standard are fulfilled. The quality management system is subject to yearly surveillance.

Report No.: 1130650-10
Effective date: 2023-05-19
Expiry date: 2026-05-18
Issue date: 2023-05-11



D. Wiedemuth
Dipl.-Ing. (FH) Daniele Wiedemuth
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany



Certificate



Quality Management System
EN ISO 13485:2016

Registration No.: SX 1483000-1

Organization: EUROIMMUN
Medizinische Labordiagnostika AG
Seekamp 31
23560 Lübeck
Germany

The scope of certification also covers the following:

No.	Facility	Scope
/01	c/o EUROIMMUN Medizinische Labordiagnostika AG Seekamp 31 23560 Lübeck Germany	Design and development and manufacture of immuno-biochemical test systems, immunofluorescence test systems, molecular diagnostic / genetic test systems, test systems for the determination of infectious agents, and instruments / software for instruments for in vitro diagnostics
/02	c/o EUROIMMUN Medizinische Labordiagnostika AG Werkstr. 1 23942 Dassow Germany	Design and development, manufacture and distribution of immuno-biochemical test systems, immunofluorescence test systems, molecular diagnostic / genetic test systems, test systems for the determination of infectious agents, and instruments / software for in vitro diagnostics
/03	c/o EUROIMMUN Medizinische Labordiagnostika AG An der Trave 1 23923 Selmsdorf Germany	Design and development, manufacture, service and distribution of immuno-biochemical test systems, immunofluorescence test systems and instruments / software for in vitro diagnostics

Report No.: 1130650-10
Effective date: 2023-05-19
Expiry date: 2026-05-18
Issue date: 2023-05-11



D. Wiedemuth
Dipl.-Ing. (FH) Daniele Wiedemuth
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany



Certificate



Quality Management System
EN ISO 13485:2016

Registration No.: SX 1483000-1

Organization: EUROIMMUN
Medizinische Labordiagnostika AG
Seekamp 31
23560 Lübeck
Germany

The scope of certification also covers the following:

- | | | |
|-----|--|---|
| /04 | c/o EUROIMMUN
Medizinische Labordiagnostika AG
Am Sonnenberg 9
23627 Groß Grönau
Germany | Manufacture of immunofluorescence test systems for in vitro diagnostics |
| /05 | c/o EUROIMMUN
Medizinische Labordiagnostika AG
Am Born 24
23627 Groß Grönau
Germany | Design and development of software for in vitro diagnostics |
| /06 | c/o EUROIMMUN
Medizinische Labordiagnostika AG
Im Kreppel 1
02747 Herrnhut
Germany | Manufacture of immuno-biochemical test systems and immunofluorescence test systems for in vitro diagnostics |
| /07 | c/o EUROIMMUN
Medizinische Labordiagnostika AG
Am Pließnitztal 1
02748 Bernstadt
Germany | Manufacture of immuno-biochemical test systems and instruments for in vitro diagnostics |

Report No.: 1130650-10
Effective date: 2023-05-19
Expiry date: 2026-05-18
Issue date: 2023-05-11



D. Wiedemuth

Dipl.-Ing. (FH) Daniele Wiedemuth
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany



Certificate

Quality Management System
EN ISO 13485:2016

Registration No.: SX 1483000-1

Organization: EUROIMMUN
Medizinische Labordiagnostika AG
Seekamp 31
23560 Lübeck
Germany

The scope of certification also covers the following:

/08 c/o EUROIMMUN
Medizinische Labordiagnostika AG
Schloßstr. 11
91257 Pegnitz
Germany

Manufacture of immunofluorescence test systems, installation and service of instruments / software for in vitro diagnostic

/09 c/o EUROIMMUN
Medizinische Labordiagnostika AG
Am Flugplatz 4
23560 Lübeck
Germany

Design and development, installation, service and distribution of immuno-biochemical test systems, immunofluorescence test systems, molecular diagnostic / genetic test systems, test systems for the determination of infectious agents, and instruments / software for in vitro diagnostics

/10 c/o EUROIMMUN
Medizinische Labordiagnostika AG
Gewerbestr. 19
23942 Dassow
Germany

Manufacture of sheet metal and other components for instruments for in vitro diagnostics

Report No.: 1130650-10
Effective date: 2023-05-19
Expiry date: 2026-05-18
Issue date: 2023-05-11



D. Wiedemuth

Dipl.-Ing. (FH) Daniele Wiedemuth
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany

Certificate

Quality Management System
EN ISO 13485:2016

Registration No.: SX 1483000-1

Organization: EUROIMMUN
Medizinische Labordiagnostika AG
Seekamp 31
23560 Lübeck
Germany

The scope of certification also covers the following:

/11 c/o EUROIMMUN
Medizinische Labordiagnostika AG
Am Berzdorfer See 7
02829 Markersdorf
Germany

Warehousing of immuno-biochemical test
systems and instruments for in vitro
diagnostics

TÜVRheinland

Report No.: 1130650-10
Effective date: 2023-05-19
Expiry date: 2026-05-18
Issue date: 2023-05-11



D. Wiedemuth
Dipl.-Ing. (FH) Daniele Wiedemuth
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany



Declaration of Conformity

EUROIMMUN Medizinische Labordiagnostika AG
Seekamp 31, 23560 Lübeck, Germany

declares under its sole responsibility as manufacturer that the ELISA product

Anti-Treponema pallidum ELISA (IgM)

EI 2111-9601 M

(product name, order number)

meets the following demands of:

Directive 98/79/EC on in vitro diagnostic medical devices of 27 October 1998 and its transpositions in national laws which apply to it.

Conformity assessment procedure: Annex III

This Declaration of Conformity is valid based on the respective currently valid version of technical documentation.

Lübeck, May 17, 2022

(Place and date of issue)

Dr. Ewald Müller-Kunert
- Head of Quality Management -

Susanne Aleksandrowicz
- Member of the Executive Board -



Declaration of Conformity

EUROIMMUN Medizinische Labordiagnostika AG
Seekamp 31, 23560 Lübeck, Germany

declares under its sole responsibility as manufacturer that the ELISA product

Anti-Treponema pallidum ELISA (IgG)
(product name, order number)

EI 2111-9601 G

meets the following demands of:

*Directive 98/79/EC on in vitro diagnostic medical devices of 27 October 1998 and
its transpositions in national laws which apply to it.*

Conformity assessment procedure: Annex III

This Declaration of Conformity is valid based on the respective currently valid version of technical documentation.

Lübeck, May 17, 2022
(Place and date of issue)


Dr. Ewald Müller-Kunert
- Head of Quality Management -


Susanne Aleksandrowicz
- Member of the Executive Board -



Declaration of Conformity

EUROIMMUN Medizinische Labordiagnostika AG
Seekamp 31, 23560 Lübeck, Germany

declares under its sole responsibility as manufacturer that the Blot product:

Anti-Treponema pallidum EUROLINE-WB (IgM)

DY 2111-####-1 M

(product name, order number)

meet the following demands of:


Directive 98/79/EC on in vitro diagnostic medical devices of 27 October 1998 and its transpositions in national laws which apply to it.

Conformity assessment procedure: Annex III

This Declaration of Conformity is valid based on the respective currently valid version of technical documentation.

Lübeck, 25.04.2022

(Place and date of issue)


Dr. Ewald Müller-Kunert
- Head of Quality Management
and Regulatory Affairs -


Susanne Aleksandrowicz
- Member of the Executive Board -



Declaration of Conformity

EUROIMMUN Medizinische Labordiagnostika AG
Seekamp 31, 23560 Lübeck, Germany

declares under its sole responsibility as manufacturer that the Blot product:

Anti-Treponema pallidum EUROLINE-WB (IgG)

DY 2111-####-1 G

(product name, order number)


meet the following demands of:

Directive 98/79/EC on in vitro diagnostic medical devices of 27 October 1998 and its transpositions in national laws which apply to it.

Conformity assessment procedure: Annex III

This Declaration of Conformity is valid based on the respective currently valid version of technical documentation.

Lübeck, 25.04.2022
(Place and date of issue)


Dr. Ewald Müller-Kunert
- Head of Quality Management
and Regulatory Affairs -


Susanne Aleksandrowicz
- Member of the Executive Board -

Anti-Treponema pallidum ELISA (IgM)

Test instruction




ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
EI 2111-9601 M	Treponema pallidum	IgM	Ag-coated microplate wells	96 x 01 (96)

Indication: The ELISA test kit provides a semiquantitative in vitro assay for human antibodies of the immunoglobulin class IgM against *Treponema pallidum* in serum or plasma for the diagnosis of infections with *Treponema pallidum*, associated diseases: Lues.

Application: The Anti-Treponema pallidum ELISA (IgM) is suitable as a confirmatory test in the framework of a 2-step strategy for the specific detection of *Treponema pallidum* infections, but can also be used as specific screening or exclusionary test.

Principle of the test: The test kit contains microtiter strips each with 8 break-off reagent wells coated with purified recombinant antigens of *Treponema pallidum*. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgM antibodies (also IgA and IgG) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	
2. Calibrator (IgM, human), ready for use	dark red	1 x 2.0 ml	
3. Positive control (IgM, human), ready for use	blue	1 x 2.0 ml	
4. Negative control (IgM, human), ready for use	green	1 x 2.0 ml	
5. Enzyme conjugate peroxidase-labelled anti-human IgM (goat), ready for use	red	1 x 12 ml	
6. Sample buffer buffer containing IgG/RF-absorbent (anti-human IgG antibody preparation obtained from goat), ready for use	green	1 x 100 ml	
7. Wash buffer 10x concentrate	colourless	1 x 100 ml	
8. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	
9. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	
10. Protective foil	---	2 pieces	
11. Quality control certificate	---	1 protocol	
12. Test instruction	---	1 booklet	

 Lot description		 Storage temperature
 In vitro diagnostic medical device		 Unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents should be disposed of according to official regulations.



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below.

The thermostat adjusted ELISA incubator must be set at +37°C ± 1°C.

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrator and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use. The green coloured sample buffer contains IgG/RF absorbent. Serum or plasma samples diluted with this sample buffer are only to be used for the determination of IgM antibodies.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallisation occurs in the concentrated buffer, warm it to +37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionised or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light ☀. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Warning: The calibrator and controls of human origin have tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the agent sodium azide in a non-declarable concentration. Avoid skin contact.



Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Introduction: Before the determination of specific antibodies of class IgM, antibodies of class IgG should be removed from the patient sample. This procedure must be carried out in order to prevent any rheumatoid factors of class IgM from reacting with specifically bound IgG, which would lead to false positive IgM test results, and to prevent specific IgG displacing IgM from the antigen, which would lead to false IgM-negative test results.

Functional principle: The sample buffer (green coloured!) contains an anti-human antibody preparation from goat. IgG from a serum sample is bound with high specificity by these antibodies and precipitated. If the sample also contains rheumatoid factors, these will be absorbed by the IgG/anti-human IgG complex.

Separation properties:

- All IgG subclasses are bound and precipitated by the anti-human IgG antibodies.
- Human serum IgG in concentrations of up to 15 mg per ml are removed (average serum IgG concentration in adults: 12 mg per ml).
- Rheumatoid factors are also removed.
- The recovery rate of the IgM fraction is almost 100%.

Performance: The **patient samples** for analysis are diluted **1:101** with green coloured sample buffer. For example, add 10 µl sample to 1.0 ml sample buffer and mix well by vortexing. Sample pipettes are not suitable for mixing. Incubate the mixture for at least **10 minutes** at room temperature (+18°C to +25°C). Subsequently, it can be pipetted into the microplate wells according to the pipetting protocol.

Notes:

- Antibodies of the class IgG should not be analysed with this mixture.
- It is possible to check the efficacy of the IgG/RF absorbent for an individual patient sample by performing an IgG test in parallel to the IgM test using the mixture. If the IgG test is negative, the IgM result can be considered as reliable.
- The calibrator and controls are ready for use, do not dilute them.



Incubation

(Partly) manual test performance

Sample incubation: (1st step)

Transfer 100 µl of the calibrator, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol.

For manual processing of microplate wells, cover the finished test plate with the protective foil. When using an automated microplate processor for incubation follow the recommendations of the instrument manufacturer.

Incubate **60 minutes** at $+37^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

Washing:

Manual: Remove the protective foil, empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.

Automatic: Remove the protective foil and wash the reagent wells 3 times with 450 µl of working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Mode").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Note: Residual liquid ($> 10\text{ }\mu\text{l}$) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short residence times) can lead to false high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2nd step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgM) into each of the microplate wells. Incubate for **30 minutes** at room temperature ($+18^{\circ}\text{C}$ to $+25^{\circ}\text{C}$).

Washing:

Empty the wells. Wash as described above.

Substrate incubation: (3rd step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature ($+18^{\circ}\text{C}$ to $+25^{\circ}\text{C}$) (protect from direct sunlight).

Stopping:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a **wavelength of 450 nm** and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.

Test performance using fully automated analysis devices

Sample dilution and test performance are carried out fully automatically using an analysis device. The incubation conditions programmed in the respective software authorised by EUROIMMUN may deviate slightly from the specifications given in the ELISA test instruction. However, these conditions were validated in respect of the combination of the EUROIMMUN Analyzer I, Analyzer I-2P or the DSX from Dynex and this EUROIMMUN ELISA. Validation documents are available on enquiry. Automated test performance using other fully automated, open-system analysis devices is possible. However, the combination should be validated by the user.

Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	C	P 6	P 14	P 22								
B	pos.	P 7	P 15	P 23								
C	neg.	P 8	P 16	P 24								
D	P 1	P 9	P 17									
E	P 2	P 10	P 18									
F	P 3	P 11	P 19									
G	P 4	P 12	P 20									
H	P 5	P 13	P 21									

The above pipetting protocol is an example of the semiquantitative analysis of antibodies in 24 patient samples (P 1 to P 24).

Calibrator (C), positive (pos.) and negative (neg.) control as well as the patient samples have been incubated in one well each. The reliability of the ELISA test can be improved by duplicate determinations of each sample. The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimises reagent wastage. Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

The extinction value of the calibrator defines the upper limit of the reference range of non-infected persons (**cut-off**) recommended by EUROIMMUN. Values above the indicated cut-off are to be considered as positive, those below as negative.

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of calibrator. Use the following formula to calculate the ratio:

Extinction of the control or patient sample
Extinction of calibrator

= Ratio

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	negative
Ratio ≥0.8 to <1.1:	borderline
Ratio ≥1.1:	positive

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another, EUROIMMUN recommends retesting the samples.

A negative serological result does not exclude an infection. Particularly in the early phase of an infection, antibodies may not yet be present or are only present in such small quantities that they are not detectable. In case of a borderline result, a secure evaluation is not possible. If there is a clinical suspicion and a negative test result, we recommend clarification by means of other diagnostic methods and/or the serological investigation of a follow-up sample. A positive result indicates that there has been contact with the pathogen. In the determination of pathogen-specific IgM antibodies, polyclonal stimulation of the immune system or antibody persistence may affect the diagnostic relevance of positive findings. Significant titer increases (exceeding factor 2) and/or seroconversion in a follow-up sample taken after 7 to 10 days can indicate an acute infection. To investigate titer changes, sample and follow-up sample should be incubated in adjacent wells of the ELISA microplate within the same test run. For diagnosis, the clinical picture of the patient always needs to be taken into account along with the serological findings.

Test characteristics

Calibration: As no quantificated international reference serum exists for antibodies against *Treponema pallidum*, results are provided in the form of ratios which are a relative measure for the concentration of antibodies in the serum or plasma. The calibration is based on internal reference sera which were used in the evaluation of the test system. The international standard for Human Syphilis Serum; 1. International standard preparation SSI code number HS reacts with ratio 4.0.

For every group of tests performed, the extinction values of the calibrator and the ratio of the positive and negative controls must lie within the limits stated for the relevant test kit lot. A quality control certificate containing these reference values is included. If the values specified for the control sera are not achieved, the test results may be inaccurate and the test should be repeated.

The binding activity of the antibodies and the activity of the enzyme used are temperature-dependent. It is therefore recommended using a thermostat in all three incubation steps. The higher the room temperature (+18°C to +25°C) during the incubation steps, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrator is subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigens: The microplate wells were coated with a mixture of four antigens of *Treponema pallidum*: p15, p17, p47 and TmpA. The corresponding cDNAs were expressed in *E. coli* as recombinant antigens.

Detection limit: The lower detection limit is defined as the mean value of an analyte-free sample plus three times the standard deviation and is the smallest detectable antibody titer. The lower detection limit of the Anti-*Treponema pallidum* ELISA (IgM) is ratio 0.06.

Cross reactivity: The quality of the antigen used ensures a high specificity and sensitivity of the ELISA. Sera from patients with infections caused by various agents were investigated with the Anti-*Treponema pallidum* ELISA (IgM). This ELISA showed no cross reactivity.

Antibodies against	n	Anti- <i>Treponema pallidum</i> ELISA (IgM) positive
Borrelia burgdorferi	10	0%
CMV	8	0%
EBV-CA	10	0%
HSV-1/2	2	0%
Measles virus	10	0%
Mumps virus	9	0%
Parvovirus B19	7	0%
Rubella virus	10	0%
Toxoplasma gondii	10	0%
VZV	4	0%

Interference: Haemolytic, lipaemic and icteric samples showed no influence on the result up to a concentration of 10 mg/ml for haemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation (CV) using 3 samples. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

Intra-assay variation, n = 20		
Sample	Mean value (Ratio)	CV (%)
1	1.1	4.4
2	3.3	4.2
3	6.1	3.9

Inter-assay variation, n = 4 x 6		
Sample	Mean value (Ratio)	CV (%)
1	1.2	5.8
2	3.5	5.4
3	6.2	4.6

Sensitivity and specificity: 72 clinically pre-characterised patient samples (INSTAND and RfB) were investigated with the EUROIMMUN Anti-Treponema pallidum ELISA (IgM). The sensitivity amounted to 100%, with a specificity of 100%. Borderline results were not included in the calculation.

n = 72		INSTAND/RfB		
		positive	borderline	negative
EUROIMMUN Anti-Treponema pallidum ELISA (IgM)	positive	17	0	0
	borderline	0	1	0
	negative	0	1	53

The specificity of the Anti-Treponema pallidum ELISA (IgM) was evaluated in a study performed on 37 patient sera which were seropositive for rheumatoid factors. None of the 37 samples tested positive using the Anti-Treponema pallidum ELISA (IgM).

Reference range: The levels of the anti-Treponema pallidum antibodies (IgM) were analysed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off ratio of 1.0, 0.2% of the blood donors were anti-Treponema pallidum positive (IgM).

Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

Clinical significance

Treponema pallidum pallidum is a helically wound bacteria of the Spirochaeta family. This family includes five genera: Borrelia, Spirochaeta, Cristispira, Treponema and Leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection occurring in tropical regions called frambesia; T. pallidum carateum is the causative agent of Pinta.

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found in 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis.

Syphilis is transmitted from human to human during sexual acts via the mucosa. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata). Syphilis is a known risk factor for abortions and stillbirths.

The disease is divided into different stages, the number of which varies in literature, depending on the world region. In German-speaking regions four stages are differentiated (primary, secondary, tertiary and quaternary stage). In Asia and sometimes in the USA, stages three and four are combined into the



tertiary stage. The secondary stage has a wider meaning and is subdivided into an early latent and a late latent phase.

The early latent stage is described as seroreactive, asymptomatic and infectious (approx. one year after infection), while the late latent phase is characterised as seroreactive, asymptomatic and non-infectious (more than one year after infection). In Central Europe the infection is divided into the following four stages:

Primary stage: The *ulcus durum* (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the pathogen (e.g. penis). It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the clearly defined fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (*Treponema pallidum* haemagglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II. **Secondary stage:** Approximately 8 weeks after the infection, the disease manifests itself with flu-like symptoms such as fever, fatigue or headache and joint pain. In addition to a generalised swelling of the lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules which mainly affect skin folds. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, keratitis, iritis, hepatitis, vasculitis, and myocardial disorders.

All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years.

Tertiary stage: Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivascularitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis, and periosteitis.

Quaternary stage: Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetative disorders.

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum*.

Treponema pallidum pallidum has a length of 5 to 15 μm and a width of 0.2 μm with 10 to 20 turns and can rotate around its longitudinal axis. Due to its fine structure, it is difficult to make it visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved.

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye.

When this screening test is positive, further serological investigation is recommended to confirm the result, either using the Anti-*Treponema pallidum* FTA-Abs Test or using state-of-the-art procedures such as the Anti-*Treponema pallidum* ELISA or the Anti-*Treponema pallidum* Westernblot (e.g. Anti-*Treponema pallidum* EUROLINE-WB). Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB).

Antibodies against *Treponema pallidum* can be detected in serum and in CSF. This is diagnostically relevant, for example, in children with congenital syphilis. For the quantitative in vitro detection of human antibodies of immunoglobulin class IgG against *Treponema pallidum* in CSF, the same ELISA as used for the determination of antibodies against *Treponema pallidum* in serum is suitable. When determining an infection of the CNS it is necessary to differentiate between intrathecally produced antibodies and antibodies which have migrated from the blood into CSF.



The intrathecal pathogen-specific antibody production is defined by the relative CSF/serum quotient CSQrel (synonym: antibody specificity index). The quotient is calculated from the ratio of agent-specific antibodies to total IgG in CSF in proportion to the ratio of agent-specific antibodies to total IgG in serum. With this method a *Treponema pallidum* infection in the CNS can be easily and reliably determined.

Literature references

1. Brown DL, Frank JE. **Diagnosis and management of syphilis.** Am Fam Physician 68 (2003) 283-290.
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of *Treponema pallidum* subspecies.** J Clin Microbiol 44 (2006) 3377-3380.
3. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
4. Department of Health and Human Services. CDC. **Syphilis – Physician’s Pocket Guide.** www.cdc.gov/std/see/.
5. EUROIMMUN AG. **Testkit für die Labordiagnostik.** Deutsches Gebrauchsmuster DE 20 2012 004 404 (angemeldet 2012).
6. Herbert LJ, Middleton SL. **An estimate of syphilis incidence in Eastern Europe.** J Glob Health 2 (2012) 10402. 1-7.
7. Kent ME, Romanelli F. **Reexamining syphilis: an update on epidemiology, clinical manifestations, and management.** Ann Pharmacother 42 (2008) 226-236.
8. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
9. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
10. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a *Treponema pallidum*-specific IgM enzyme immunoassay and *Treponema pallidum* western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
11. Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn HJ, Lewis DA, Notermans DW, Riis J, Robertson P, Seppälä IJ, Rijpkema S. **Evaluation of two human plasma pools as candidate international standard preparations for syphilitic antibodies.** Biologicals 37 (2009) 245-251.
12. EUROIMMUN AG. Stöcker W, Ehling T. **Vorrichtung und Verfahren zur Untersuchung einer biologischen Probe.** Deutsche Patentanmeldung DE 10 2011 011 795.4 (angemeldet 2011).
13. Stöcker* W, Fauer* H, Krause* C, Barth E, Martinez A. (*EUROIMMUN AG). **Verfahren zur Optimierung der automatischen Fluoreszenzerkennung in der Immundiagnostik.** Deutsche Patentanmeldung (Offenlegungsschrift) DE 10 2006 027 516.0 und WO2007140952 (2006).
14. Sun R, Lai DH, Ren RX, Lian S, Zhang HP. ***Treponema pallidum*-specific antibody expression for the diagnosis of different stages of syphilis.** Chin Med J (Engl) 126 (2013) 206-210.



Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.

Technical Support

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).

Additional information

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.



Anti-Treponema pallidum ELISA (IgG)

Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG-CLASS	SUBSTRATE	FORMAT
EI 2111-9601 G	Treponema pallidum	IgG	Ag-coated microplate wells	96 x 01 (96)

Indication: Infection with Treponema pallidum, associated diseases: Lues.

Principles of the test: The ELISA test kit provides a semiquantitative or quantitative in vitro assay for human antibodies of the IgG class against Treponema pallidum in serum or plasma. The test kit contains microtiter strips each with 8 break-off reagent wells coated with purified recombinant antigens of Treponema pallidum. In the first reaction step, diluted patient samples are incubated in the wells. In the case of positive samples, specific IgG antibodies (also IgA and IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate), catalysing a colour reaction.

Contents of the test kit:

Component	Colour	Format	Symbol
1. Microplate wells coated with antigens: 12 microplate strips each containing 8 individual break-off wells in a frame, ready for use	---	12 x 8	STRIPS
2. Calibrator 1 200 RU/ml (IgG, human), ready for use	dark red	1 x 2.0 ml	CAL 1
3. Calibrator 2 20 RU/ml (IgG, human), ready for use	red	1 x 2.0 ml	CAL 2
4. Calibrator 3 2 RU/ml (IgG, human), ready for use	light red	1 x 2.0 ml	CAL 3
5. Positive control (IgG, human), ready for use	blue	1 x 2.0 ml	POS CONTROL
6. Negative control (IgG, human), ready for use	green	1 x 2.0 ml	NEG CONTROL
7. Enzyme conjugate peroxidase-labelled anti-human IgG (rabbit), ready for use	green	1 x 12 ml	CONJUGATE
8. Sample buffer ready for use	light blue	1 x 100 ml	SAMPLEBUFFER
9. Wash buffer 10x concentrate	colourless	1 x 100 ml	WASHBUFFER 10x
10. Chromogen/substrate solution TMB/H ₂ O ₂ , ready for use	colourless	1 x 12 ml	SUBSTRATE
11. Stop solution 0.5 M sulphuric acid, ready for use	colourless	1 x 12 ml	STOP SOLUTION
12. Test instruction	---	1 booklet	
13. Protocol with reference values	---	1 protocol	
14. Protective foil	---	2 pieces	
LOT Lot	•	Storage temperature	
IVD In vitro determination		Unopened usable until	

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C. Do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Patient samples, calibrators, controls and incubated microplate strips should be handled as infectious waste. All reagents should be disposed of according to official regulations.



Preparation and stability of the reagents

Note: All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. After first use, the reagents are stable until the indicated expiry date if stored at +2°C to +8°C and protected from contamination, unless stated otherwise below. The thermostat adjusted ELISA incubator must be set at 37 °C +/- 1 °C

- **Coated wells:** Ready for use. Tear open the resealable protective wrapping of the microplate at the recesses above the grip seam. Do not open until the microplate has reached room temperature to prevent the individual strips from moistening. Immediately replace the remaining wells of a partly used microplate in the protective wrapping and tightly seal with the integrated grip seam (Do not remove the desiccant bag).
Once the protective wrapping has been opened for the first time, the wells coated with antigens can be stored in a dry place and at a temperature between +2°C and +8°C for 4 months.
- **Calibrators and controls:** Ready for use. The reagents must be mixed thoroughly before use.
- **Enzyme conjugate:** Ready for use. The enzyme conjugate must be mixed thoroughly before use.
- **Sample buffer:** Ready for use.
- **Wash buffer:** The wash buffer is a 10x concentrate. If crystallization occurs in the concentrated buffer, warm it to 37°C and mix well before diluting. The quantity required should be removed from the bottle using a clean pipette and diluted with deionized or distilled water (1 part reagent plus 9 parts distilled water).
For example: For 1 microplate strip, 5 ml concentrate plus 45 ml water.
The working strength wash buffer is stable for 4 weeks when stored at +2°C to +8°C and handled properly.
- **Chromogen/substrate solution:** Ready for use. Close the bottle immediately after use, as the contents are sensitive to light. The chromogen/substrate solution must be clear on use. Do not use the solution if it is blue coloured.
- **Stop solution:** Ready for use.

Warning: Calibrators and controls used have been tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2 using enzyme immunoassays and indirect immunofluorescence methods. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the toxic agent sodium azide. Avoid skin contact.

Preparation and stability of the patient samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: Patient samples are diluted **1:101** sample buffer. For example: dilute 10 µl serum in 1.0 ml sample buffer and mix well by vortexing (sample pipettes are not suitable for mixing).

NOTE: Calibrators and controls are prediluted and ready for use, do not dilute them.



Incubation

For **semiquantative analysis** incubate **calibrator 2** along with the positive and negative controls and patient samples. For **quantitative analysis** incubate **calibrators 1, 2 and 3** along with the positive and negative controls and patient samples.

Sample incubation: (1. step)

Transfer 100 µl of the calibrators, positive and negative controls or diluted patient samples into the individual microplate wells according to the pipetting protocol.

For manual processing of microplate wells, cover the finished test plate with the protective foil. When using an automated microplate processor for incubation, follow the instrument manufacturer's recommendations with regard to microwell plate sealing.

Incubate **60 minutes** at $37^{\circ}\text{C} \pm 1^{\circ}\text{C}$.

Wash:

Manual: Remove the protective foil and empty the wells and subsequently wash 3 times using 300 µl of working strength wash buffer for each wash.

Automatic: Remove the protective foil and empty the wells and subsequently wash 3 times with 450 µl working strength wash buffer (program setting: e.g. TECAN Columbus Washer "Overflow Modus").

Leave the wash buffer in each well for 30 to 60 seconds per washing cycle, then empty the wells. After washing (manual and automated tests), thoroughly dispose of all liquid from the microplate by tapping it on absorbent paper with the openings facing downwards to remove all residual wash buffer.

Attention: Residual liquid ($> 10 \mu\text{l}$) in the reagent wells after washing can interfere with the substrate and lead to false low extinction values. Insufficient washing (e.g., less than 3 wash cycles, too small wash buffer volumes, or too short reaction times) can lead to false high extinction values.

Free positions on the microplate strip should be filled with blank wells of the same plate format as that of the parameter to be investigated.

Conjugate incubation: (2. step)

Pipette 100 µl of enzyme conjugate (peroxidase-labelled anti-human IgG) into each of the microplate wells. Incubate for **30 minutes** at room temperature ($+18^{\circ}\text{C}$ to 25°C).

Wash:

Empty the wells. Wash as described above.

Substrate incubation: (3. step)

Pipette 100 µl of chromogen/substrate solution into each of the microplate wells. Incubate for **15 minutes** at room temperature ($+18^{\circ}\text{C}$ to 25°C) (protect from direct sunlight).

Stopping the reaction:

Pipette 100 µl of stop solution into each of the microplate wells in the same order and at the same speed as the chromogen/substrate solution was introduced.

Measurement:

Photometric measurement of the colour intensity should be made at a wavelength of 450 nm and a reference wavelength between 620 nm and 650 nm **within 30 minutes of adding the stop solution**. Prior to measuring, slightly shake the microplate to ensure a homogeneous distribution of the solution.



Pipetting protocol

	1	2	3	4	5	6	7	8	9	10	11	12
A	K2	P 6	P 14	P 22			K 1	P 4	P 12	P 20		
B	pos.	P 7	P 15	P 23			K 2	P 5	P 13	P 21		
C	neg.	P 8	P 16	P 24			K 3	P 6	P 14	P 22		
D	P 1	P 9	P 17				pos.	P 7	P 15	P 23		
E	P 2	P 10	P 18				neg.	P 8	P 16	P 24		
F	P 3	P 11	P 19				P 1	P 9	P 17			
G	P 4	P 12	P 20				P 2	P 10	P 18			
H	P 5	P 13	P 21				P 3	P 11	P 19			

The pipetting protocol for microtiter strips 1-4 is an example for the semiquantitative analysis of 24 patient samples (P 1 to P 24).
The pipetting protocol for microtiter strips 7-10 is an example for the quantitative analysis of 24 patient samples (P 1 to P 24).

The calibrators (C 1 to C 3), the positive (pos.) and negative (neg.) controls, and the patient samples have each been incubated in one well. The reliability of the ELISA test can be improved by duplicate determinations for each sample.
The wells can be broken off individually from the strips. This makes it possible to adjust the number of test substrates used to the number of samples to be examined and minimizes reagent wastage.
Both positive and negative controls serve as internal controls for the reliability of the test procedure. They should be assayed with each test run.

Calculation of results

Semiquantitative: Results can be evaluated semiquantitatively by calculating a ratio of the extinction value of the control or patient sample over the extinction value of the calibrator 2. Calculate the ratio according the following formula:

Extinction of the control or patient sample
Extinction of calibrator 2


= Ratio

EUROIMMUN recommends interpreting results as follows:

Ratio <0.8:	negative
Ratio ≥0.8 to <1.1:	borderline
Ratio ≥1.1:	positive

In cases of borderline test results, an additional patient sample should be taken 7 days later and re-tested in parallel with the first patient sample. The results of both samples allow proper evaluation of titer changes.

Quantitative: The standard curve from which the concentration of antibodies in the patient samples can be taken is obtained by point-to-point plotting of the extinction values measured for the 3 calibration sera against the corresponding units (linear/linear). Use “point-to-point” plotting for calculation of the standard curve by computer. The following plot is an example of a typical calibration curve. Please do not use this curve for the determination of antibody concentrations in patient samples.



If the extinction of a serum sample lies above the value of calibrator 1 (200 RU/ml). The result should be given as “>200 RU/ml”. It is recommended that the sample be re-tested at a dilution of 1:400. The result in RU/ml read from the calibration curve for this sample must then be multiplied by a factor of 4.

The upper limit of the normal range of non-infected persons (**cut-off value**) recommended by EUROIMMUN is **20 relative units (RU)/ml**. EUROIMMUN recommends interpreting results as follows:

<16 RU/ml:	negative
≥16 to <22 RU/ml:	borderline
≥22 RU/ml:	positive

For duplicate determinations the mean of the two values should be taken. If the two values deviate substantially from one another the sample should be retested.

For diagnosis, the clinical symptoms of the patient should always be taken into account along with the serological results.

Test characteristics

Calibration: As no quantificated international reference serum exists for antibodies against Treponema pallidum, the calibration is performed in relative units (RU). The international standard for Human Syphilis Serum; 1. international standard preparation SSI code number HS reacts with >200 RU/ml. Using dilution curve result would be 1882 RU/ml.

For every group of tests performed, the extinction values of the calibrators and the relative units and/or ratio determined for the positive and negative controls must lie within the limits stated for the relevant test kit lot. A protocol containing these reference values is included. If the values specified for the control sera are not achieved, the test results may be inaccurate and the test should be repeated.

The activity of the enzyme used is temperature-dependent and the extinction values may vary if a thermostat is not used. The higher the room temperature during substrate incubation, the greater will be the extinction values. Corresponding variations apply also to the incubation times. However, the calibrators are subject to the same influences, with the result that such variations will be largely compensated in the calculation of the result.

Antigens: The microplate wells were coated with a mixture of four antigens of Treponema pallidum: p15, p17, p47 and TmpA. The corresponding cDNAs were expressed in E. coli as recombinant antigens.



Linearity: The linearity of the Anti-Treponema pallidum ELISA (IgG) was determined by assaying 4 serial dilutions of 6 serum samples. The linear regression was calculated and R² amounts to > 0.95 in all samples. The Anti-Treponema pallidum ELISA (IgG) is linear at least in the tested concentration range (19 RU/ml to 166 RU/ml).

Detection limit: The detection limit is defined as a value of three times the standard deviation of an analyte-free sample and is the smallest detectable antibody titer. The lower detection limit of the Anti-Treponema pallidum ELISA (IgG) is 0.3 RU/ml.

Cross reactivity: The quality of the antigen used ensures a high specificity and sensitivity of the ELISA. Sera from patients with infections caused by various agents were investigated with the Anti-Treponema pallidum ELISA (IgG). This ELISA showed no cross reactivity.

Parameter	HSV-1	EBV-CA	CMV	VZV	Adenovirus	RSVi	Parainfl. Pool	Influenza A
n	12	12	12	12	12	12	12	12
Anti-Treponema pallidum ELISA (IgG)	0	0	0	0	0	0	0	0

Parameter	Influenza B	Mycoplasma pn.	Mumps	Measles	Rubella	Toxoplasma gondii	Chlamydia pneu.	Helicobacter pyl.
n	12	12	12	12	12	12	12	12
Anti-Treponema-pallidum-ELISA (IgG)	0	0	0	0	0	0	0	0

Interference: Haemolytic, lipaemic and icteric samples showed no influence at the result up to a concentration of 10 mg/ml for hemoglobin, 20 mg/ml for triglycerides and 0.4 mg/ml for bilirubin in this ELISA.

Reproducibility: The reproducibility of the test was investigated by determining the intra- and inter-assay coefficients of variation using 3 sera. The intra-assay CVs are based on 20 determinations and the inter-assay CVs on 4 determinations performed in 6 different test runs.

Intra-assay variation, n = 20		
Serum	Mean value (RU/ml)	CV (%)
1	45	3.1
2	139	1.7
3	146	1.7

Inter-assay variation, n = 4 x 6		
Serum	Mean value (RU/ml)	CV (%)
1	43	5.2
2	145	3.2
3	150	2.8

Specificity and sensitivity: 75 clinically characterized patient samples (interlaboratory test samples from INSTAND, Labquality Finland) were examined with the EUROIMMUN Anti-Treponema pallidum ELISA (IgG). The test showed a specificity and a sensitivity of 100% each. Values for 2 of the samples were borderline and were not included in the calculation.

n = 75		INSTAND / LABQUALITY		
		positive	borderline	negative
EUROIMMUN ELISA	positive	46	0	0
	borderline	2	0	0
	negative	0	0	27

139 clinically characterized patient samples were examined with the EUROIMMUN Anti-Treponema pallidum ELISA (IgG). The specificity with respect to the reference method was 100%, with a sensitivity of 98.6%.

n = 139		TPHA	
		positive	negative
EUROIMMUN ELISA	positive	137	0
	negative	2	0

Reference range: The levels of the anti-Treponema pallidum antibodies (IgG) were analyzed with this EUROIMMUN ELISA in a panel of 500 healthy blood donors. With a cut-off of 20 RU/ml, 0.4 % of the blood donors were anti-Treponema pallidum positive (IgG) which reflects the known percentage of infections in adults.

Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

Clinical significance

Treponema pallidum is a helically wound bacteria of the Spirochaeta family [1]. This family includes five genera: borrelia, spirochaeta, cristispira, treponema and leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection occurring in tropical regions called framboesia; T. pallidum carateum is the causative agent of Pinta [2, 3, 4].

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found In 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis [1].

Syphilis is transmitted from human to human during sexual acts via the mucosa [1, 5]. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata) [1, 6, 7, 8, 9]. Syphilis is a known risk factor for abortions and stillbirths [7, 10].

Primary stage: The ulcus durum (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the virus (e.g. penis) [1]. It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the defined, limited fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (Treponema pallidum haemagglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II [1].

Secondary stage: Approximately 8 weeks after the infection, the disease manifests itself with flu-like symptoms such as fever, fatigue or head and joint pains. In addition to a generalised swelling of the lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules, which mainly affect skin folds [1]. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, ketaritis, iritis, hepatitis, vasculitis, and myocardial disorders [1].



All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years [1].

Tertiary stage: Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivascularitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis, and periosteitis.

Quaternary stage: Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetational disorders [1].

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum* [1].

Treponema pallidum pallidum has a length of 5-15µm and a width of 0.2µm with 10-20 turns and can rotate around its longitudinal axis [1]. Due to its fine structure, it is difficult to be made visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved [1].

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye [1, 11, 12].

If the screening test is positive, additional testing is recommended e.g. using an FTA-ABS assay. For further serological diagnosis, modern serological test methods such as anti-*Treponema pallidum* ELISA, Westernblot, e.g. EUROLINE WB, and IIFT have become widely accepted and have proven successful [1, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34]. Antibodies can be found in the serum and CSF, particularly in children having congenital syphilis [6, 8, 9, 20, 35]. Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB) [36, 37, 38, 39, 40, 41, 42].

Literature references

1. Hahn H, Miksits K. **Treponemen**. In: Hahn, Falke, Kaufmann, Ullmann. Medizinische Mikrobiologie und Infektiologie. Springer 5. Auflage (2005).
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of *Treponema pallidum* subspecies**. J Clin Microbiol 44 (2006) 3377-3380.
3. Leader BT, Hevner K, Molini BJ, Barrett LK, Van Voorhis WC, Lukehart SA. **Antibody responses elicited against the *Treponema pallidum* repeat proteins differ during infection with different isolates of *Treponema pallidum* subsp. *Pallidum***. Infect Immun 71 (2003) 6054-6057.
4. Sun ES, Molini BJ, Barrett LK, Centurion-Lara A, Lukehart SA, Van Voorhis WC. **Subfamily I *Treponema pallidum* repeat protein family: sequence variation and immunity**. Microbes Infect 6 (2004) 725-737.
5. Pajaro MC, Barberis IL, Godino S, Pascual L, Aguero M. **Epidemiology of sexually transmitted diseases in Rio Cuarto, Argentina**. Rev Latinoam Microbiol 43 (2001) 157-160.
6. Sanchez PJ, Wendel GD, Norgard MV. **IgM antibody to *Treponema pallidum* in cerebrospinal fluid of infants with congenital syphilis**. Am J Dis Child 146 (1992) 1171-1175.
7. Pankratov OV, Saluk YV, Klimova LV. **Epidemiology of syphilis in pregnant women and congenital syphilis in Belarus**. Acta Dermatovenereol Alp Panonica Adriat 15 (2006) 35-38.



8. Michelow IC, Wendel GD Jr, Norgard MV, Zeray F, Leos NK, Alsaadi R, Sanchez PJ. **Central nervous system infection in congenital syphilis.** N Engl J Med 346 (2002) 1792-1798.
9. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
10. Folgosa E, Osman NB, Gonzalez C, Hagerstrand I, Bergstrom S, Ljungh A. **Syphilis seroprevalence among pregnant women and its role as a risk factor for stillbirth in Maputo, Mozambique.** Genitourin Med 72 (1996) 339-342.
11. Castro R, Prieto ES, Joao Aguas M, Jose Manata M, Botas J, Araujo C, Borges F, Aldir I, Exposto Fda L. **Evaluation of the Treponema pallidum particle agglutination technique (TP.PA) in the diagnosis of neurosyphilis.** J Clin Lab Anal 20 (2006) 233-238.
12. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
13. Lewis LL, Taber LH, Baughn RE. **Evaluation of immunoglobulin M western blot analysis in the diagnosis of congenital syphilis.** J Clin Microbiol 28 (1990) 296-302.
14. Kaiser R, Rauer S. **Serodiagnosis of neuroborreliosis: comparison of reliability of three confirmatory assays.** Infection 27 (1999) 177-182.
15. Lewis LL, Taber LH, Baughn RE. **Evaluation of Immunoglobulin M Western Blot Analysis in the Diagnosis of Congenital Syphilis.** J Clin Microbiol 28 (1990) 296-302.
16. Muller F. **Treponema pallidum IgM enzyme-linked immunosorbent assay (TP-IgM-ELISA). Determination of organism-specific Treponema IgM antibodies in the serum of syphilis patients with and without central nervous system involvement of the infection.** [Article in German] Z Hautkr 58 (1983) 1689-1708.
17. Merlin S, Poncet F, Alacoque B, Guinet R, Andre J. **Treponemal antigens detected by immunoblotting with serum and CSF antibodies of neurosyphilitic patients.** Ann Inst Pasteur Microbiol 138 (1987) 709-717.
18. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
19. Kaiser R, Rauer S. **Serodiagnosis of neuroborreliosis: comparison of reliability of three confirmatory assays.** Infection 27 (1999) 177-182.
20. Schmitz JL, Gertis KS, Mauney C, Stamm LV, Folds JD. **Laboratory diagnosis of congenital syphilis by immunoglobulin M (IgM) and IgA immunoblotting.** Clin Diagn Lab Immunol 1 (1994) 32-37.
21. Marangoni A, Sambri V, Storni E, D'Antuono A, Negosanti M, Cevenini R. **Treponema pallidum surface immunofluorescence assay for serologic diagnosis of syphilis.** Clin Diagn Lab Immunol 7 (2000) 417-421.
22. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
23. Meyer W, Scheper T, Lehmann Heike (Erfinder). **Selbstklebende Blotmembran.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 20215268.5 (2002).
24. Meyer W, Scheper T (Erfinder). **Vorrichtung zur Antikörperdiagnose mit kombinierten Membranen.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 20215270.7 (2002).
25. Morrin M, Rateike Martin, Müller M (Erfinder). **Lichtquelle für ein Auflichtfluoreszenzmikroskop.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen 202004010121.1 (2004).



26. Müller M, Wessel S, Morrin M (Erfinder). **Konstante Lichtquelle für die Fluoreszenzmikroskopie.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen DE 10 2006 027 518.7 (2006).
27. Stöcker W, Rateike M, Morrin M. (Erfinder). **Verfahren zur Herstellung Festphasen-gebundener Bioreagenzien.** EUROIMMUN Medizinische Labordiagnostika AG. Patent. Aktenzeichen PCT/EP2005/000974 - EP 1718 948 (2005).
28. Young H, Moyes A, McMillan A, Patterson J. **Enzyme immunoassay for anti-treponemal IgG: screening or confirmatory test?** J Clin Pathol 45 (1992) 37-41.
29. Enders M, Hagedorn HJ. **Syphilis in pregnancy.** [Article in German] Z Geburtshilfe Neonatol 206 (2002) 131-137.
30. Hagedorn HJ. **MiQ 16/2001 Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik: Syphilis.** Urban & Fischer Verlag München Jena. (2001).
31. Hagedorn HJ. **Aktuelle Aspekte der Syphilisdiagnostik.** Immun Infekt 21 (1993) 94-99.
32. Hagedorn HJ. **Serodiagnostik der Syphilis.** Diagnose u. Labor 45 (1995) 94-104.
33. Müller F, Hagedorn HJ. **Syphilis.** In: Thomas L (Hrsg) Labor und Diagnose. TH-Books Frankfurt/Main (1998) 1232-1241.
34. Schmidt BL, Edjlalipour M, Luger A. **Comparative evaluation of nine different enzyme-linked immunosorbent assays for determination of antibodies against Treponema pallidum in patients with primary syphilis.** J Clin Microbiol 38 (2000) 1279-1282.
35. Meyer PM, Eddy T, Baughn RE. **Analysis of Western Blotting (Immunoblotting) Technique in Diagnosis of Congenital Syphilis.** J Clin Microbiol 32 (1994) 629-633.
36. Angue Y, Yaueib A, Mola G, Duke T, Amoa AB. **Syphilis serology testing: a comparative study of Abbot Determine, Rapid Plasma Reagin (RPR) card test and Venereal Disease Research Laboratory (VDRL) methods.** P N G Med J 48 (2005) 168-173.
37. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
38. Stöcker W. **TITERPLANE Vorrichtung zur Durchführung von Mikroanalysen.** Europäisches Patent Nr. EP 0 018 435 (1979). Übersetzt ins Englische, Französische und Schwedische.
39. Stöcker W. **TITERPLANE Apparatus and method for simultaneously mixing specimens for performing microanalyses.** USA-Patent Nr. 4,339,241 (1980/1982); patentiert auch in Japan.
40. Mabey D, Peeling RW, Ballard R, Benzaken AS, Galban E, Chantalucha J, Everett D, Balira R, Fitzgerald D, Joseph P, Nerette S, Li J, Zheng H. **Prospective, multi-centre clinic-based evaluation of four rapid diagnostic tests for syphilis.** Sex Transm Infect 82 (2006) 13-16.
41. Serwin AB, Kohl PK, Chodyncka B. **The centenary of Wassermann reaction--the future of serological diagnosis of syphilis, up-to-date studies.** [Article in Polish] Przegl Epidemiol 59 (2005) 633-640.
42. Cervera R, Asherson RA. **Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics.** Immunobiology 210 (2005) 735-741.

Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.



Technical Support

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).

Additional information

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.

Anti-Treponema pallidum WESTERNBLOT (IgM)

Instructions for use

ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
DY 2111-1601 M DY 2111-2401 M	Treponema pallidum	IgM	Antigen coated membrane strips	16 x 01 (16) 24 x 01 (24)

Indication: The WESTERNBLOT test kit provides a qualitative in vitro assay for human antibodies of the immunoglobulin class IgM against Treponema pallidum in serum or plasma to support the diagnosis of infections with Treponema pallidum and associated diseases (lues).

Principles of the test: The test kit contains test strips with electrophoretically separated antigens of Treponema pallidum. The blot strips will be blocked and incubated in the first reaction step with diluted patient samples. In the case of positive samples, specific antibodies of the class IgM (and IgA, IgG) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgM (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Format	Format	Symbol
1. Test strips Single strips with electrophoretically separated Treponema pallidum antigens	16 x 1	24 x 1	
2. Evaluation matrix with control strip Test strip incubated with a positive control serum	1 pattern	1 pattern	---
3. Enzyme conjugate Alkaline phosphatase-labelled anti-human IgM (goat), 10x concentrate	1 x 3 ml	2 x 3 ml	
4. Universal buffer, 10x concentrate	1 x 50 ml	1 x 100 ml	
5. Substrate solution Nitroblue tetrazolium chloride/5-Bromo-4-chloro-3-indolylphosphate (NBT/BCIP), ready for use	1 x 30 ml	1 x 50 ml	
6. Incubation tray	2 x 8 channels	3 x 8 channels	
7. Instructions for use	1 booklet	1 booklet	---
 Lot description			 Storage temperature
 In vitro diagnostic medical device			 Unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C and +8°C, do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Undiluted patient sera and incubated blot strips should be handled as infectious waste. Other reagents do not need to be collected separately, unless stated otherwise in official regulations.



The following components are not provided in the test kits but can be ordered at EUROIMMUN under the respective order numbers. Performance of the test requires an **incubation tray**:

ZD 9895-0130 Incubation tray with 30 channels (black)

ZD 9898-0144 Incubation tray with 44 channels (black, for the EUROBlotOne and EUROBlotCamera system)

For the creation of work protocols and the evaluation of incubated test strips using **EUROLineScan** green paper and adhesive foil are required:

ZD 9880-0101 Green paper (1 sheet)

ZD 9885-0116 Adhesive foil for approx. 16 test strips

ZD 9885-0130 Adhesive foil for approx. 30 test strips

If a **visual evaluation** is to be performed in individual cases, the required evaluation protocol can be ordered under: ZD 2111-0101 Evaluation protocol visual Anti-Treponema pallidum WESTERNBLOT.

Preparation and stability of the reagents

Note: This test kit may only be used by trained personnel. Test strips and incubation trays are intended for single use. The bag containing the blot strips is printed with a number in addition to the test kit lot number. This number refers to the strip batch and is also printed on the corresponding evaluation template. These two numbers must match to ensure correct evaluation of test results.

All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. Unopened, reagents are stable until the indicated expiry date when stored at +2°C to +8°C. After initial opening, reagents are stable for 12 months or until the expiry date, if earlier, unless stated otherwise in the instructions. Opened reagents must also be stored at +2°C to +8°C and protected from contamination.

- **Coated test strips:** Ready for use. Open the packing with the test strips only when the strips have reached room temperature (+18 °C to +25 °C) to prevent condensation on the strips. After removal of the strips the packing should be sealed tightly and stored at +2°C to +8°C. To ensure correct evaluation of results, the lot number on the bag must match the lot number on the strips as well as on the evaluation matrix.
- **Enzyme conjugate:** The enzyme conjugate is supplied as a 10x concentrate. For the preparation of the working-strength enzyme conjugate the required amount should be removed from the bottle using a clean pipette tip and diluted 1:10 with working-strength diluted universal buffer. For 1 test strip dilute 0.15 ml anti-human IgM concentrate with 1.35 ml working-strength diluted universal buffer. The working-strength diluted enzyme conjugate should be used at the same working day.
- **Universal buffer:** The universal buffer is supplied as a 10x concentrate. For the preparation of the working-strength universal buffer the required amount should be removed from the bottle using a clean pipette and diluted 1:10 with deionised or distilled water. For the incubation of 1 test strip 1.5 ml buffer concentrate should be diluted with 13.5 ml deionised or distilled water. The working-strength diluted buffer should be used at the same working day.
- **Substrate solution:** Ready for use. Close bottle immediately after use, as the contents are sensitive to light ☼.

Warning: The control of human origin, used to incubate the test strip on the evaluation protocol, has tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2. Nonetheless all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain sodium azide in a non-declarable concentration. Avoid skin contact.



Preparation and stability of the serum or plasma samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: The **patient samples** for analysis are diluted **1:51** in ready for use diluted universal buffer using a clean pipette tip. For example, add 30 µl of sample to 1.5 ml ready for use diluted universal buffer and mix well by vortexing. Sample pipettes are not suitable for mixing.

Incubation

Blocking: According to the number of serum samples to be tested fill each channel of the incubation tray with 1.5 ml ready for use diluted universal buffer and a blot strip. Remove the required amount of blot strips from the packing using a pair of tweezers. (Make sure that the surface of the test strips is not damaged!). The number on the test strip should be visible. Incubate for **15 minutes** at room temperature (+18°C to +25°C) on a rocking shaker. Afterwards aspirate off all the liquid.

Sample incubation: (1st step) Fill each channel with 1.5 ml of the diluted serum samples using a clean pipette tip. Incubate at room temperature (+18°C to +25°C) for **30 minutes** on a rocking shaker.

Wash: Aspirate off the liquid from each channel and wash **3 x 5 minutes** each with 1.5 ml working strength universal buffer on a rocking shaker.

Conjugate incubation: (2nd step) Pipette 1.5 ml ready for use diluted enzyme conjugate (alkaline phosphatase-conjugated anti-human IgM) into each channel. Incubate for **30 minutes** at room temperature (+18°C to +25°C) on a rocking shaker.

Wash: Aspirate off the liquid from each channel. Wash as described above.

Substrate incubation: (3rd step) Pipette 1.5 ml substrate solution into the channels of the incubation tray. Incubate for **10 minutes** at room temperature (+18°C to +25°C) on a rocking shaker.


Stopping: Aspirate off the liquid from each channel and wash each strip **3 x 1 minute** with deionised or distilled water.

For automated incubation with the EUROBlotMaster select the program **Euro02 Inf WB30**.

For automated incubation with the EUROBlotOne select the program **Euro01/02**.

Anti-Treponema pallidum WESTERNBLOT (IgM)

Incubation protocol



Anti-Treponema pallidum WESTERNBLOT (IgM)
Evaluation and Interpretation

Handling: For evaluation of incubated test strips we generally recommend using the **EUROLineScan** software. After stopping the reaction using deionised or distilled water, place the incubated test strips onto the adhesive foil of the green work protocol using a pair of tweezers. The position of the test strips can be corrected while they are wet. As soon as all test strips have been placed onto the protocol, they should be pressed hard using filter paper and left to air-dry. After they have dried, the test strips will be stuck to the adhesive foil. The dry test strips are then scanned using a flatbed scanner (EUROIMMUN) and evaluated with **EUROLineScan**. Alternatively, imaging and evaluation is possible directly from the incubation trays (EUROBlotCamera and EUROBlotOne). For general information about the EUROLineScan program please refer to the EUROLineScan user manual (EUROIMMUN). The code for entering the **Test** in EUROLineScan is **T_pal_WB_IgM**.

If a visual evaluation must be performed in exceptional cases, hold the evaluation matrix next to the stuck-on blot strips and position it so that the black band above the number on the blot strips lines up with the alignment bar of the evaluation matrix. **The lot number on the evaluation matrix must match the lot number on the blot strips.** Clearly recognisable bands on the blot strips which concur with the labelled bands on the evaluation matrix are noted in the evaluation protocol.

Antigens: The antigen source for the **EUROIMMUN Anti-Treponema pallidum WESTERNBLOT** is provided by particularly suitable Treponema pallidum antigen preparations. These antigens have been separated using discontinuous polyacrylamide gel electrophoresis according to molecular masses and transferred onto nitrocellulose membrane. From each nitrocellulose membrane, control blot strips have been removed and incubated with a reference sera. One of these stained strips is included in the kit, the other remains with EUROIMMUN for documentation purposes.

Specificity of the antigens on the test strips:

Band	Antigen	Specificity
47 kDa	membrane protein, TpN47	specific
45 kDa	tmpA	specific
17 kDa	membrane protein, TpN17	specific
15 kDa	membrane protein, TpN15	specific

In the lower part of the test strip there is a conjugate control membrane chip (IgA, IgG and IgM). Below the conjugate control, there is a membrane chip with a control band (Control).

Attention: A correctly performed determination of antibodies of class IgM against the antigens described above is indicated by a positive reaction of the control band and a positive reaction of the IgM band.

If one of these bands only shows a very weak reaction or none at all, the result is not valid.

IgG class antibodies against Treponema pallidum

Interpretation of results: The results of the Anti-Treponema pallidum WESTERNBLOT test can be divided into negative, borderline and positive results. In order to evaluate the signals, the band positions and intensity of staining must be taken into consideration, as negative sera sometimes produce weak signals in individual bands.

Result	Characteristics
Negative	No bands of specific antigens.
Borderline	One distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.
Positive	More than one distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.

IgM class antibodies against Treponema pallidum

Interpretation of results: The results of the Anti-Treponema pallidum WESTERNBLOT test can be divided into negative, borderline and positive results. In order to evaluate the signals, the band positions and intensity of staining must be taken into consideration, as negative sera sometimes produce weak signals in individual bands.
For the diagnosis of a fresh Treponema pallidum infection, a positive IgM result should be confirmed with a positive IgG result using a fresh blood sample 3 to 6 weeks later.

Result	Characteristics
Negative	No bands of specific antigens.
Borderline	One weak band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa. It is recommended that a fresh sample be taken and the test repeated after a few weeks.
Positive	At least one distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.

For diagnosis, the clinical picture of the patient always needs to be taken into account along with the serological findings.

Test characteristics

Measurement range: The Westernblot is a qualitative method. No measurement range is provided.

Inter- and intra-assay variation: The inter-assay and intra-assay variation were determined by multiple analyses of characterised samples over several days. The intra-assay variation was determined by multiple analyses of characterised samples on one day. In every case, the intensity of the bands was within the specified range. This Westernblot displays excellent inter- and intra-assay reproducibility.

Interference: Haemolytic, lipaemic and icteric sera showed no effect on the analytical results.

Cross reactions: The quality of the antigen substrates and the antigen source guarantee a high specificity of the Westernblot. The measurement of cross reactions is not necessary for Westernblots because with this test system a direct differentiation between specific and unspecific antigens is possible.

Specificity and sensitivity: A panel of 19 serologically defined samples, pre-characterised by an approved reference test (certified by the Paul-Ehrlich Institute) and 50 samples of healthy blood donors, all with negative results in TPHA test, were investigated with the EUROIMMUN Anti-Treponema pallidum Westernblot.

IgG	Characterised panel (see above)		
	n = 69	positive	negative
EUROIMMUN Anti-Treponema pallidum Westernblot	positive	19	0
	negative	0	50

The Anti-Treponema pallidum Westernblot IgG has a specificity of 100% and a sensitivity of 100%. The positive predictive value is 100%.

IgM	Characterised panel (see above)		
	n = 69	positive	negative
EUROIMMUN Anti-Treponema pallidum Westernblot	positive	17	1
	negative	0	51

The Anti-Treponema pallidum Westernblot IgM has a specificity of 98% and a sensitivity of 100%. The positive predictive value is 94%.

Neither IgM nor IgG antibodies against Treponema pallidum were detected in the samples of healthy blood donors.

Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

Clinical significance

Treponema pallidum pallidum is a helically wound bacterium of the Spirochaeta family. This family includes five genera: Borrelia, Spirochaeta, Cristispira, Treponema and Leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection called frambesia occurring in tropical regions; T. pallidum carateum is the causative agent of pinta.

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found in 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis.

Syphilis is transmitted from human to human during sexual acts via the mucosa. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata). Syphilis is a known risk factor for abortions and stillbirths.

The disease is divided into different stages, the number of which varies in literature, depending on the world region. In German-speaking regions four stages are differentiated (primary, secondary, tertiary and quaternary stage). In Asia and sometimes in the USA, stages three and four are combined into the tertiary stage. The secondary stage has a wider meaning and is subdivided into an early latent and a late latent phase. The early latent stage is described as seroreactive, asymptomatic and infectious (approx. one year after infection), while the late latent phase is characterised as seroreactive, asymptomatic and non-infectious (more than one year after infection). In Central Europe the infection is divided into the following four stages:

Primary stage: The ulcer durum (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the pathogen (e.g. penis). It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the clearly defined fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (Treponema pallidum haem-agglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II.

Secondary stage: Approximately 8 weeks after the infection, the disease manifests with flu-like symptoms such as fever, fatigue or headache and joint pain. In addition to a generalised swelling of the



lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules, which mainly affect skin folds. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, keratitis, iritis, hepatitis, vasculitis, and myocardial disorders.

All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years.

Tertiary stage: Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivascularitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis, and periosteitis.

Quaternary stage: Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetative disorders.

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum*.

Treponema pallidum pallidum has a length of 5 to 15 μm and a width of 0.2 μm with 10 to 20 turns and can rotate around its longitudinal axis. Due to its fine structure, it is difficult to make it visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved.

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye.

When this screening test is positive, further serological investigation is recommended to confirm the result, either using the Anti-*Treponema pallidum* FTA-Abs Test or using state-of-the-art procedures such as the Anti-*Treponema pallidum* ELISA or the Anti-*Treponema pallidum* Westernblot (e.g. Anti-*Treponema pallidum* EUROLINE-WB). Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB).

Antibodies against *Treponema pallidum* can be detected in serum and in CSF. This is diagnostically relevant, for example, in children with congenital syphilis. For the quantitative in vitro detection of human antibodies of immunoglobulin class IgG against *Treponema pallidum* in CSF, the same ELISA as used for the determination of antibodies against *Treponema pallidum* in serum is suitable. When determining an infection of the CNS it is necessary to differentiate between intrathecally produced antibodies and antibodies which have migrated from the blood into CSF. The intrathecal pathogen-specific antibody production is defined by the relative CSF/serum quotient CSQ_{rel} (synonym: antibody specificity index). The quotient is calculated from the ratio of agent-specific antibodies to total IgG in CSF in proportion to the ratio of agent-specific antibodies to total IgG in serum. With this method a *Treponema pallidum* infection in the CNS can be easily and reliably determined.



Literature

1. Brown DL, Frank JE. **Diagnosis and management of syphilis.** Am Fam Physician 68 (2003) 283-290.
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of Treponema pallidum subspecies.** J Clin Microbiol 44 (2006) 3377-3380.
3. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
4. Department of Health and Human Services. CDC. **Syphilis - Physician's Pocket Guide.** www.cdc.gov/std/see/
5. EUROIMMUN AG. **Testkit für die Labordiagnostik.** Deutsches Gebrauchsmuster DE 20 2012 004 404 (angemeldet 2012).
6. Herbert LJ, Middleton SI. **An estimate of syphilis incidence in Eastern Europe.** J Glob Health 2 (2012) 10402. 1-7.
7. Kent ME, Romanelli F. **Reexamining syphilis: an update on epidemiology, clinical manifestations, and management.** Ann Pharmacother 42 (2008) 226-236.
8. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
9. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the German infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
10. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
11. Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn HJ, Lewis DA, Notermans DW, Riis J, Robertson P, Seppälä IJ, Rijpkema S. **Evaluation of two human plasma pools as candidate international standard preparations for syphilitic antibodies.** Biologicals 37 (2009) 245-251.
12. EUROIMMUN AG. Stöcker W, Ehling T. **Vorrichtung und Verfahren zur Untersuchung einer biologischen Probe.** Deutsche Patentanmeldung DE 10 2011 011 795.4 (angemeldet 2011).
13. Stöcker* W, Fauer* H, Krause* C, Barth E, Martinez A. (*EUROIMMUN AG). **Verfahren zur Optimierung der automatischen Fluoreszenzerkennung in der Immundiagnostik.** Deutsche Patentanmeldung (Offenlegungsschrift) DE 10 2006 027 516.0 und WO2007140952 (2006).
14. Sun R, Lai DH, Ren RX, Lian S, Zhang HP. **Treponema pallidum-specific antibody expression for the diagnosis of different stages of syphilis.** Chin Med J (Engl) 126 (2013) 206-210.

Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.

Technical Support

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).

Additional information

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.



Anti-Treponema pallidum WESTERNBLOT (IgG)

Test instruction

ORDER NO.	ANTIBODIES AGAINST	IG CLASS	SUBSTRATE	FORMAT
DY 2111-1601 G DY 2111-2401 G	Treponema pallidum	IgG	Antigen coated membrane strips	16 x 01 (16) 24 x 01 (24)

Indication: The WESTERNBLOT test kit provides a qualitative in vitro assay for human antibodies of the immunoglobulin class IgG against Treponema pallidum in serum or plasma for the diagnosis of infections with Treponema pallidum and associated diseases (lues).

Application: The anti-Treponema pallidum WESTERNBLOT is suitable as a confirmatory test in a 2 step-strategy for the specific detection of a Treponema pallidum infection. Due to the use of electrophoretically purified antigens of Treponema pallidum, specific antibodies can be determined.

Principles of the test: The test kit contains test strips with electrophoretically separated antigens of Treponema pallidum. The blot strips will be blocked and incubated in the first reaction step with diluted patient samples. In the case of positive samples, specific antibodies of the class IgG (and IgA, IgM) will bind to the antigens. To detect the bound antibodies, a second incubation is carried out using an enzyme-labelled anti-human IgG (enzyme conjugate) catalysing a colour reaction.

Contents of the test kit:

Component	Format	Format	Symbol
1. Test strips Single strips with electrophoretically separated Treponema pallidum antigens	16 x 1	24 x 1	
2. Evaluation matrix with control strip Test strip incubated with a positive control serum	1 pattern	1 pattern	---
3. Enzyme conjugate Alkaline phosphatase-labelled anti-human IgG (goat), 10x concentrate	1 x 3 ml	2 x 3 ml	
4. Universal buffer, 10x concentrate	1 x 50 ml	1 x 100 ml	
5. Substrate solution Nitroblue tetrazolium chloride/5-Bromo-4-chloro-3-indolylphosphate (NBT/BCIP), ready for use	1 x 30 ml	1 x 50 ml	
6. Incubation tray	2 x 8 channels	3 x 8 channels	
7. Test instruction	1 booklet	1 booklet	---
 Lot description			 Storage temperature
 In vitro diagnostic medical device			 Unopened usable until

Storage and stability: The test kit has to be stored at a temperature between +2°C to +8°C, do not freeze. Unopened, all test kit components are stable until the indicated expiry date.

Waste disposal: Undiluted patient sera and incubated blot strips should be handled as infectious waste. Other reagents do not need to be collected separately, unless stated otherwise in official regulations.

Updates with respect to the previous version are marked in grey.



The following components are not provided in the test kits but can be ordered at EUROIMMUN under the respective order numbers. Performance of the test requires an **incubation tray**:

ZD 9895-0130 Incubation tray with 30 channels (black)

ZD 9898-0144 Incubation tray with 44 channels (black, for the EUROBlotOne and EUROBlotCamera system)

For the creation of work protocols and the evaluation of incubated test strips using **EUROLineScan** green paper and adhesive foil are required:

ZD 9880-0101 Green paper (1 sheet)

ZD 9885-0116 Adhesive foil for approx. 16 test strips

ZD 9885-0130 Adhesive foil for approx. 30 test strips

If a **visual evaluation** is to be performed in individual cases, the required evaluation protocol can be ordered under: ZD 2111-0101 Evaluation protocol visual *Treponema pallidum* WESTERNBLOT.

Preparation and stability of the reagents

Note: The bag containing the blot strips is printed with a number in addition to the test kit lot number. This number refers to the strip batch and is also printed on the corresponding evaluation template. These two numbers must match to ensure correct evaluation of test results.

All reagents must be brought to room temperature (+18°C to +25°C) approx. 30 minutes before use. Unopened, reagents are stable until the indicated expiry date when stored at +2°C to +8°C. After initial opening, reagents are stable for 12 months or until the expiry date, if earlier, unless stated otherwise in the instructions. Opened reagents must also be stored at +2°C to +8°C and protected from contamination.

- **Coated test strips:** Ready for use. Open the packing with the test strips only when the strips have reached room temperature to prevent condensation on the strips. After removal of the strips the packing should be sealed tightly and stored at +2°C to +8°C. To ensure correct evaluation of results, the lot number on the bag must match the lot number on the strips as well as on the evaluation matrix.
- **Enzyme conjugate:** The enzyme conjugate is supplied as a 10x concentrate. For the preparation of the ready for use enzyme conjugate the required amount should be removed from the bottle using a clean pipette and diluted 1:10 with ready for use diluted universal buffer. For 1 test strip dilute 0.15 ml anti-human IgG concentrate with 1.35 ml ready for use diluted universal buffer. The ready for use diluted enzyme conjugate should be used at the same working day.
- **Universal buffer:** The universal buffer is supplied as a 10x concentrate. For the preparation of the ready for use universal buffer the required amount should be removed from the bottle using a clean pipette and diluted 1:10 with deionised or distilled water. For the incubation of 1 test strip 1.5 ml buffer concentrate should be diluted with 13.5 ml deionised or distilled water. The ready for use diluted buffer should be used at the same working day.
- **Substrate solution:** Ready for use. Close bottle immediately after use, as the contents are sensitive to light ☼.

Warning: The control of human origin, used to incubate the test strip on the evaluation protocol, has tested negative for HBsAg, anti-HCV, anti-HIV-1 and anti-HIV-2. Nonetheless, all materials should be treated as being a potential infection hazard and should be handled with care. Some of the reagents contain the agent sodium azide in a non-declarable concentration. Avoid skin contact.



Preparation and stability of the serum or plasma samples

Sample material: Human serum or EDTA, heparin or citrate plasma.

Stability: Patient samples to be investigated can generally be stored at +2°C to +8°C for up to 14 days. Diluted samples should be incubated within one working day.

Sample dilution: The **patient samples** for analysis are diluted **1:51** in ready for use diluted universal buffer. For example, add 30 µl of sample to 1.5 ml ready for use diluted universal buffer and mix well by vortexing. Sample pipettes are not suitable for mixing.

Incubation

Blocking:

According to the number of serum samples to be tested fill each channel of the incubation tray with 1.5 ml ready for use diluted universal buffer and a blot strip. Remove the required amount of blot strips from the packing using a pair of tweezers. The number on the test strip should be visible.

Incubate for **15 minutes** at room temperature (+18°C to +25°C) on a rocking shaker. Afterwards aspirate off all the liquid.

Sample incubation: (1st step)

Fill each channel with 1.5 ml of the diluted serum samples.

Incubate at room temperature (+18°C to +25°C) for **30 minutes** on a rocking shaker.

Wash:

Aspirate off the liquid from each channel and wash **3 x 5 minutes** each with 1.5 ml working strength universal buffer on a rocking shaker.

Conjugate incubation: (2nd step)

Pipette 1.5 ml ready for use diluted enzyme conjugate (alkaline phosphatase-conjugated anti-human IgG) into each channel.

Incubate for **30 minutes** at room temperature (+18°C to +25°C) on a rocking shaker.

Wash:

Aspirate off the liquid from each channel. Wash as described above.

Substrate incubation: (3rd step)

Pipette 1.5 ml substrate solution into the channels of the incubation tray.

Incubate for **10 minutes** at room temperature (+18°C to +25°C) on a rocking shaker.

Stopping:


Aspirate off the liquid from each channel and wash each strip **3 x 1 minute** with deionised or distilled water.

For automated incubation with the EUROBlotMaster select the program **Euro02 Inf WB30**.

For automated incubation with the EUROBlotOne select the program **Euro01/02**.

Anti-Treponema pallidum WESTERNBLOT (IgG)

Incubation protocol



Anti-Treponema pallidum WESTERNBLOT (IgG)
Evaluation and Interpretation

Handling: For evaluation of incubated test strips we generally recommend using the **EUROLineScan** software. After stopping the reaction using deionised or distilled water, place the incubated test strips onto the adhesive foil of the green work protocol using a pair of tweezers. The position of the test strips can be corrected while they are wet. As soon as all test strips have been placed onto the protocol, they should be pressed hard using filter paper and left to air-dry. After they have dried, the test strips will be stuck to the adhesive foil. The dry test strips are then scanned using a flatbed scanner (EUROIMMUN AG) and evaluated with **EUROLineScan**. Alternatively, imaging and evaluation is possible directly from the incubation trays (EUROBlotCamera and EUROBlotOne). For general information about the EUROLineScan program please refer to the EUROLineScan user manual (EUROIMMUN AG). The code for entering the **Test** in EUROLineScan is **T_pal_WB_IgG**.

If a visual evaluation must be performed in exceptional cases, hold the evaluation matrix next to the stuck-on blot strips and position it so that the black band above the number on the blot strips lines up with the alignment bar of the evaluation matrix. **The lot number on the evaluation matrix must match the lot number on the blot strips.** Clearly recognisable bands on the blot strips which concur with the labelled bands on the evaluation matrix are noted in the evaluation protocol.

Antigens: The antigen source for the **EUROIMMUN Anti-Treponema pallidum WESTERNBLOT** is provided by a particularly suitable Treponema pallidum antigen preparation. This antigen has been solubilised using sodium dodecyl sulphate followed by a separation of the solubilised protein using discontinuous polyacrylamide gel electrophoresis according to molecular mass and transfer of the separated proteins to nitrocellulose. From each test kit, 2 control test strips have been removed and incubated with a reference serum. One of these stained strips is included in the kit, the other remains with EUROIMMUN for documentation purposes.

Specificity of the antigens on the test strips:

Band	Antigen	Specificity
47 kDa	membrane protein, TpN47	specific
45 kDa	tmpA	specific
17 kDa	membrane protein, TpN17	specific
15 kDa	membrane protein, TpN15	specific

In the lower part of the test strip there is a conjugate control membrane chip (IgA, IgG and IgM). Below the conjugate control, there is a membrane chip with a control band (Control).

Attention: A correctly performed determination of antibodies of class IgG against the antigens described above is indicated by a positive reaction of the control band and a positive reaction of the IgG band.

If one of these bands only shows a very weak reaction or none at all, the result is not valid.

IgG class antibodies against Treponema pallidum

Interpretation of results: The results of the Anti-Treponema pallidum WESTERNBLOT test can be divided into negative, borderline and positive results. In order to evaluate the signals, the band positions and intensity of staining must be taken into consideration, as negative sera sometimes produce weak signals in individual bands.

Result	Characteristics
Negative	No bands of specific antigens.
Borderline	One distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.
Positive	More than one distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.

IgM class antibodies against Treponema pallidum

Interpretation of results: The results of the Anti-Treponema pallidum WESTERNBLOT test can be divided into negative, borderline and positive results. In order to evaluate the signals, the band positions and intensity of staining must be taken into consideration, as negative sera sometimes produce weak signals in individual bands.

For the diagnosis of a fresh Treponema infection, a positive IgM result should be confirmed with a positive IgG result using a fresh blood sample 3 to 6 weeks later.

Result	Characteristics
Negative	No bands of specific antigens.
Borderline	One weak band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa. It is recommended that a fresh sample be taken and the test repeated after a few weeks.
Positive	At least one distinctive band of the specific antigens: p15 kDa, p17 kDa, p45 kDa or p47 kDa.

For diagnosis, the clinical picture of the patient always needs to be taken into account along with the serological findings.

Test characteristics

Measurement range: The Westernblot is a qualitative method. No measurement range is provided.

Inter- and intra-assay variation: The inter-assay variation was determined by multiple analyses of characterised samples over several days. The intra-assay variation was determined by multiple analyses of characterised samples on one day. In every case, the intensity of the bands was within the specified range. This Westernblot displays excellent inter- and intra-assay reproducibility.

Interference: Haemolytic, lipaemic and icteric sera showed no effect on the analytical results.

Cross reactions: The quality of the antigen substrates and the antigen source guarantee a high specificity of the Westernblot. The measurement of cross reactions is not necessary for Westernblots because with this test system a direct differentiation between specific and unspecific antigens is possible.

Specificity and sensitivity: A panel of 19 serologically defined samples, pre-characterised by an approved reference test (certified by the Paul-Ehrlich Institute) and 50 samples of healthy blood donors, all with negative results in TPHA test, were investigated with the EUROIMMUN Anti-Treponema pallidum Westernblot.

IgG	Characterised panel (see above)		
	n = 69	positive	negative
EUROIMMUN Anti-Treponema pallidum Westernblot	positive	19	0
	negative	0	50

The Anti-Treponema pallidum WESTERNBLOT IgG has a specificity of 100% and a sensitivity of 100%. The positive predictive value is 100%.

IgM	n = 69	Characterised panel (see above)	
		positive	negative
EUROIMMUN Anti-Treponema pallidum Westernblot	positive	17	1
	negative	0	51

The Anti-Treponema pallidum Westernblot IgM has a specificity of 98% and a sensitivity of 100%. The positive predictive value is 94%.

Neither IgM nor IgG antibodies against Treponema pallidum were detected in the samples of healthy blood donors.

Limitations of the procedure

The test is not intended to be used for the determination of suitability for transfusion, transplantation or cell administration.

Clinical significance

Treponema pallidum pallidum is a helically wound bacteria of the Spirochaeta family. This family includes five genera: Borrelia, Spirochaeta, Cristispira, Treponema and Leptospira. Treponema pallidum is the causative agent of syphilis or lues, a chronic infectious disease. The subspecies T. pallidum endemicum causes venereal syphilis; T. pallidum pertenue leads to a non-venereal infection occurring in tropical regions called frambesia; T. pallidum carateum is the causative agent of pinta.

In 1905 Fritz Schaudinn (German zoologist, 1871-1906) and Erich Hoffmann (German dermatologist, 1868-1959) at the Charité in Berlin were the first to detect the causative agent of syphilis under the microscope. Spirochaeta were first found in 1913 by the Japanese microbiologist and physician Noguchi Hideyo (1876-1928) in the brain tissue of a patient with progressive paralysis.

Syphilis is transmitted from human to human during sexual acts via the mucosa. Indirect transmission by blood transfusions and wounds is also possible. During pregnancy and at birth the baby can become infected by the mother (syphilis connata). Syphilis is a known risk factor for abortions and still-births.

The disease is divided into different stages, the number of which varies in literature, depending on the world region. In German-speaking regions four stages are differentiated (primary, secondary, tertiary and quaternary stage). In Asia and sometimes in the USA, stages three and four are combined into the tertiary stage. The secondary stage has a wider meaning and is subdivided into an early latent and a late latent phase. The early latent stage is described as seroreactive, asymptomatic and infectious (approx. one year after infection), while the late latent phase is characterised as seroreactive, asymptomatic and non-infectious (more than one year after infection). In Central Europe the infection is divided into the following four stages:

Primary stage: The ulcer durum (hard-edged ulcer) is characteristic of the primary lesion of the syphilis (stage I) and normally occurs 3 weeks after infection, developing at the place of entry of the pathogen (e.g. penis). It is a painless ulcer, which contains large quantities of the pathogen and is therefore highly contagious. Typically, the clearly defined fibrous or crusted erosion has a raised hard edge. The possible swelling of the regional lymph nodes is painless and the lymph nodes remain displaceable. From that time on, the disease can be diagnosed e.g. using the TPHA test (Treponema pallidum haemagglutination assay). After 2 to 6 weeks the ulcer heals leaving a scar. The infection generally persists and develops into stage II.

Secondary stage: Approximately 8 weeks after the infection, the disease manifests with flu-like symptoms such as fever, fatigue or headache and joint pain. In addition to a generalised swelling of the



lymph nodes, 90% of patients show local or generalised skin disorders, which are accompanied by weak or no itching. At first, light pink patches form, which further evolve into hard, coppery nodules (papules). In the foreground are condylomata lata, broad papules which mainly affect skin folds. The liquid excreted by open and weeping papules is highly contagious. Additionally, various organ disorders may develop, for example, keratitis, iritis, hepatitis, vasculitis, and myocardial disorders. All skin disorders (syphilids) heal after approximately 4 months. Secondary syphilis is followed by a clinically silent stage (syphilis latens), which can last for years.

Tertiary stage: Typical manifestations of a *Treponema pallidum* infection in stage III are large papules and ulcers on the skin and mucous membranes, as well as organ or visceral syphilis, including gummatous and interstitial inflammation, perivascularitis, cardiovascular syphilis, neurosyphilis (asymptomatic and symptomatic form), osteitis and periosteitis.

Quaternary stage: Ten to thirty years after an untreated infection, 8% to 10% of patients experience severe neurological disorders such as neurosyphilis with progressive paralysis and Tabes dorsalis with severe mental and vegetative disorders.

The **diagnosis** of syphilis is based on clinical findings according to the disease stage, microscopic detection of the infectious agent (dark field), and the serological detection of antibodies against *Treponema pallidum*.

Treponema pallidum has a length of 5 to 15 μm and a width of 0.2 μm with 10 to 20 turns and can rotate around its longitudinal axis. Due to its fine structure, it is difficult to make it visible under the microscope by staining. However, living bacteria can be investigated using dark field microscopy. Detection in cultures has not yet been achieved.

The TPHA (*Treponema pallidum* haemagglutination assay) is an assay for the indirect determination of antibodies against *Treponema pallidum*. Erythrocytes marked with proteins and polysaccharides of *Treponema pallidum* on their surface are mixed with patient serum. The presence of antibodies against *Treponema pallidum* in the patient serum causes agglutination of the erythrocytes (haemagglutination), which is visible to the naked eye.

When this screening test is positive, further serological investigation is recommended to confirm the result, either using the Anti-*Treponema pallidum* FTA-Abs Test or using state-of-the-art procedures such as the Anti-*Treponema pallidum* ELISA or the Anti-*Treponema pallidum* Westernblot (e.g. Anti-*Treponema pallidum* EUROLINE-WB). Antibodies against cardiolipin serve as an activity marker of the infection (VDRL or RPR test, EUROLINE WB).

Antibodies against *Treponema pallidum* can be detected in serum and in CSF. This is diagnostically relevant, for example, in children with congenital syphilis. For the quantitative in vitro detection of human antibodies of immunoglobulin class IgG against *Treponema pallidum* in CSF, the same ELISA as used for the determination of antibodies against *Treponema pallidum* in serum is suitable. When determining an infection of the CNS it is necessary to differentiate between intrathecally produced antibodies and antibodies which have migrated from the blood into CSF. The intrathecal pathogen-specific antibody production is defined by the relative CSF/serum quotient CSQ_{rel} (synonym: antibody specificity index). The quotient is calculated from the ratio of agent-specific antibodies to total IgG in CSF in proportion to the ratio of agent-specific antibodies to total IgG in serum. With this method a *Treponema pallidum* infection in the CNS can be easily and reliably determined.



Literature references

1. Brown DL, Frank JE. **Diagnosis and management of syphilis.** Am Fam Physician 68 (2003) 283-290.
2. Centurion-Lara A, Molini BJ, Godornes C, Sun E, Hevner K, Van Voorhis WC, Lukehart SA. **Molecular differentiation of Treponema pallidum subspecies.** J Clin Microbiol 44 (2006) 3377-3380.
3. Dang Q, Feng J, Lu X, Zhang X, Xu H, Liu C, Nu X. **Evaluation of specific antibodies for early diagnosis and management of syphilis.** Int J Dermatol 45 (2006) 1169-1171.
4. Department of Health and Human Services. CDC. **Syphilis - Physician's Pocket Guide.** www.cdc.gov/std/see/.
5. EUROIMMUN AG. **Testkit für die Labordiagnostik.** Deutsches Gebrauchsmuster DE 20 2012 004 404 (angemeldet 2012).
6. Herbert LJ, Middleton SI. **An estimate of syphilis incidence in Eastern Europe.** J Glob Health 2 (2012) 10402. 1-7.
7. Kent ME, Romanelli F. **Reexamining syphilis: an update on epidemiology, clinical manifestations, and management.** Ann Pharmacother 42 (2008) 226-236.
8. Manavi K, Young H, McMillan A. **The sensitivity of syphilis assays in detecting different stages of early syphilis.** Int J STD AIDS 17 (2006) 768-771.
9. Muller I, Brade V, Hagedorn HJ, Straube E, Schorner C, Frosch M, Hlobil H, Stanek G, Hunfeld KP. **Is serological testing a reliable tool in laboratory diagnosis of syphilis? Meta-analysis of eight external quality control surveys performed by the german infection serology proficiency testing program.** J Clin Microbiol 44 (2006) 1335-1341.
10. Rawstron SA, Mehta S, Bromberg K. **Evaluation of a Treponema pallidum-specific IgM enzyme immunoassay and Treponema pallidum western blot antibody detection in the diagnosis of maternal and congenital syphilis.** Sex Transm Dis 31 (2004) 123-126.
11. Rigsby P, Ison C, Brierley M, Ballard R, Hagedorn HJ, Lewis DA, Notermans DW, Riis J, Robertson P, Seppälä IJ, Rijpkema S. **Evaluation of two human plasma pools as candidate international standard preparations for syphilitic antibodies.** Biologicals 37 (2009) 245-251.
12. EUROIMMUN AG. Stöcker W, Ehling T. **Vorrichtung und Verfahren zur Untersuchung einer biologischen Probe.** Deutsche Patentanmeldung DE 10 2011 011 795.4 (angemeldet 2011).
13. Stöcker* W, Fauer* H, Krause* C, Barth E, Martinez A. (*EUROIMMUN AG). **Verfahren zur Optimierung der automatischen Fluoreszenzerkennung in der Immundiagnostik.** Deutsche Patentanmeldung (Offenlegungsschrift) DE 10 2006 027 516.0 und WO2007140952 (2006).
14. Sun R, Lai DH, Ren RX, Lian S, Zhang HP. **Treponema pallidum-specific antibody expression for the diagnosis of different stages of syphilis.** Chin Med J (Engl) 126 (2013) 206-210.

Liability

The test kit, including original accessories, must only be used in accordance with the intended use. EUROIMMUN accepts no liability for any other use (e.g. non-compliance with the instructions for use and improper use) or for resulting damages.

Technical Support

In case of technical problems you can obtain assistance via the EUROIMMUN website (<https://www.euroimmun.de/en/contact/>).



Additional information

Regulatory information for customers in the European Union: Please observe the obligation to report any serious incidents occurring in connection with this product to the competent authorities and to EUROIMMUN.



